Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for DNLI

Stock Name	Denali Therapeutics Inc
Ticker	DNLI(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US24823R1059
LEI	549300ZTQ2HO18L3Q830

Show aggregate DNLI holdings

News associated with DNLI

Financial Survey: Denali Therapeutics (NASDAQ:DNLI) & Celcuity (NASDAQ:CELC): Denali Therapeutics (NASDAQ:DNLI – Get Free Report) and Celcuity (NASDAQ:CELC – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations. Analyst Ratings This is a summary of current ratings […] - 2025-09-17 02:12:56
Denali Therapeutics (NASDAQ:DNLI) Receives “Overweight” Rating from Cantor Fitzgerald: Cantor Fitzgerald restated their overweight rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a research note released on Monday morning,Benzinga reports. Other research analysts have also recently issued reports about the company. TD Cowen raised Denali Therapeutics to a “strong-buy” rating in a report on Monday, July 28th. Morgan Stanley dropped their […] - 2025-09-09 02:50:44
Denali Therapeutics (NASDAQ:DNLI) Upgraded at TD Cowen: Denali Therapeutics (NASDAQ:DNLI – Get Free Report) was upgraded by TD Cowen to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports. DNLI has been the subject of a number of other reports. Cantor Fitzgerald raised shares of Denali Therapeutics from a “neutral” rating to an “overweight” rating in a research […] - 2025-07-30 02:20:44
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of “Buy” by Brokerages: Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) has received an average rating of “Buy” from the seventeen analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company. […] - 2025-07-29 02:30:59
New York State Common Retirement Fund Has $955,000 Stake in Denali Therapeutics Inc. (NASDAQ:DNLI): New York State Common Retirement Fund decreased its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 51.5% in the first quarter, HoldingsChannel reports. The firm owned 70,240 shares of the company’s stock after selling 74,484 shares during the period. New York State Common Retirement Fund’s holdings in Denali Therapeutics were worth $955,000 at […] - 2025-07-25 04:56:54
DekaBank Deutsche Girozentrale Raises Position in Denali Therapeutics Inc. (NASDAQ:DNLI): DekaBank Deutsche Girozentrale raised its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 7.4% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 64,210 shares of the company’s stock after acquiring an additional 4,410 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Denali Therapeutics were worth $935,000 as of its most […] - 2025-07-14 06:44:51
Denali Therapeutics Inc. (NASDAQ:DNLI) CEO Ryan J. Watts Sells 495,282 Shares: Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) CEO Ryan J. Watts sold 495,282 shares of Denali Therapeutics stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.00, for a total value of $7,429,230.00. Following the completion of the transaction, the chief executive officer owned 253,071 shares […] - 2025-07-14 05:10:49
LABU's Holdings Imply 58% Gain Potential: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-10 07:59:01
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $33.71 Average PT from Brokerages: Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) has earned an average recommendation of “Buy” from the seventeen research firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating […] - 2025-06-12 02:28:50
Analysts Anticipate VB To Hit $270: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-09 08:43:39
Two Sigma Advisers LP Acquires Shares of 15,100 Denali Therapeutics Inc. (NASDAQ:DNLI): Two Sigma Advisers LP acquired a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 15,100 shares of the company’s stock, valued at approximately $308,000. Other hedge funds also recently bought […] - 2025-06-06 05:12:49
Squarepoint Ops LLC Purchases 14,896 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI): Squarepoint Ops LLC grew its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 44.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 48,619 shares of the company’s stock after buying an additional 14,896 shares during the quarter. Squarepoint […] - 2025-06-01 05:31:11
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 3,411 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI): MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 4.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 85,075 shares of the company’s stock after purchasing an additional 3,411 shares during […] - 2025-05-23 06:26:52
Janus Henderson Group PLC Purchases 7,900 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI): Janus Henderson Group PLC grew its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 15.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 60,028 shares of the company’s stock after purchasing an additional 7,900 shares during the quarter. Janus Henderson Group PLC’s […] - 2025-05-23 05:26:51
Bank of America Cuts Denali Therapeutics (NASDAQ:DNLI) Price Target to $27.00: Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its price objective reduced by research analysts at Bank of America from $28.00 to $27.00 in a report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Bank of America‘s price objective suggests a potential upside of 88.94% from the stock’s current […] - 2025-05-21 02:56:58
Deutsche Bank AG Buys 37,907 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI): Deutsche Bank AG boosted its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 15.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 277,853 shares of the company’s stock after purchasing an additional 37,907 shares during the period. Deutsche Bank AG’s holdings in Denali Therapeutics were worth $5,663,000 as of its most […] - 2025-05-19 05:06:53
Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Bought by Northern Trust Corp: Northern Trust Corp grew its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 10.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,201,518 shares of the company’s stock after acquiring an additional 115,876 shares during the […] - 2025-05-13 05:28:54
Denali Therapeutics (NASDAQ:DNLI) Trading Down 10.1% Following Weak Earnings: Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report)’s stock price was down 10.1% on Tuesday following a dissappointing earnings announcement. The stock traded as low as $14.41 and last traded at $14.38. Approximately 525,609 shares changed hands during trading, a decline of 52% from the average daily volume of 1,084,610 shares. The stock had previously […] - 2025-05-08 03:08:47
Dimensional Fund Advisors LP Has $37.81 Million Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI): Dimensional Fund Advisors LP lifted its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 19.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,855,036 shares of the company’s stock after purchasing an additional 295,594 shares during the period. […] - 2025-05-05 05:20:52
Sterling Capital Management LLC Has $36,000 Stake in Denali Therapeutics Inc. (NASDAQ:DNLI): Sterling Capital Management LLC raised its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 589.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,773 shares of the company’s stock after purchasing an additional 1,516 shares during the quarter. Sterling […] - 2025-04-25 05:34:52
Franklin Resources Inc. Decreases Position in Denali Therapeutics Inc. (NASDAQ:DNLI): Franklin Resources Inc. reduced its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 6.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,862 shares of the company’s stock after selling 5,179 shares during the period. […] - 2025-04-15 04:56:57
Pictet Asset Management Holding SA Grows Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI): Pictet Asset Management Holding SA raised its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 17.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,356 shares of the company’s stock after buying an additional 2,806 shares during the […] - 2025-04-10 05:37:07
Sei Investments Co. Lowers Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI): Sei Investments Co. decreased its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 8.5% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 24,047 shares of the company’s stock after selling 2,229 shares during the quarter. Sei Investments Co.’s holdings in Denali Therapeutics were worth $490,000 at the end of the […] - 2025-04-10 04:18:49
1,065,608 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Purchased by Norges Bank: Norges Bank bought a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 1,065,608 shares of the company’s stock, valued at approximately $21,717,000. Several other hedge funds also recently made changes to their […] - 2025-04-07 04:51:10
Schroder Investment Management Group Has $5.02 Million Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI): Schroder Investment Management Group increased its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 94.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 247,800 shares of the company’s stock after purchasing an additional 120,494 shares during the […] - 2025-04-06 05:29:07
Corebridge Financial Inc. Sells 4,665 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI): Corebridge Financial Inc. lowered its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 7.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,800 shares of the company’s stock after selling 4,665 shares during the quarter. […] - 2025-04-04 05:09:15
American Century Companies Inc. Buys 29,155 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI): American Century Companies Inc. raised its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 6.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 480,529 shares of the company’s stock after buying an additional 29,155 shares during the period. American Century Companies Inc.’s […] - 2025-04-03 04:32:51
Teacher Retirement System of Texas Purchases 5,987 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI): Teacher Retirement System of Texas grew its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 18.6% in the 4th quarter, Holdings Channel reports. The fund owned 38,178 shares of the company’s stock after buying an additional 5,987 shares during the period. Teacher Retirement System of Texas’ holdings in Denali Therapeutics were […] - 2025-03-31 05:00:58
Cibc World Markets Corp Purchases Shares of 11,633 Denali Therapeutics Inc. (NASDAQ:DNLI): Cibc World Markets Corp acquired a new position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,633 shares of the company’s stock, valued at approximately $237,000. Other large investors have also modified their holdings […] - 2025-03-26 06:09:01
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Recommendation of “Moderate Buy” by Brokerages: Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the eighteen research firms that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation, fifteen have assigned a buy recommendation and one has assigned a strong buy […] - 2025-03-26 04:26:42

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc DNLI holdings

Date	Number of DNLI Shares Held	Base Market Value of DNLI Shares	Local Market Value of DNLI Shares	Change in DNLI Shares Held	Change in DNLI Base Value	Current Price per DNLI Share Held	Previous Price per DNLI Share Held
2025-09-26 (Friday)	29,096	USD 405,889	USD 405,889
2025-09-25 (Thursday)	29,096	USD 390,759	USD 390,759	0	USD -1,455	USD 13.43	USD 13.48
2025-09-24 (Wednesday)	29,096	USD 392,214	USD 392,214
2025-09-17 (Wednesday)	28,908	USD 377,538	USD 377,538	0	USD -5,782	USD 13.06	USD 13.26
2025-09-16 (Tuesday)	28,908	USD 383,320	USD 383,320
2025-09-12 (Friday)	28,720	USD 407,537	USD 407,537
2025-09-11 (Thursday)	28,720	USD 425,630	USD 425,630

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of DNLI by Blackrock for IE00B3VWM098

Show aggregate share trades of DNLI

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-08-21 SELL -94 15.230* 17.87 Profit of 1,680 on sale
2025-07-31 BUY 282 13.830* 17.92
2025-06-30 SELL -188 13.990* 18.38 Profit of 3,456 on sale
2025-06-25 SELL -94 14.450* 18.47 Profit of 1,736 on sale
2025-06-20 SELL -188 13.890* 18.56 Profit of 3,490 on sale
2025-05-23 BUY 94 13.420* 19.30
2025-05-19 SELL -94 13.910* 19.49 Profit of 1,832 on sale
2025-05-15 SELL -282 14.160* 19.59 Profit of 5,524 on sale
2025-05-12 SELL -94 14.800* 19.73 Profit of 1,855 on sale
2025-05-09 SELL -94 14.370* 19.78 Profit of 1,859 on sale
2025-04-30 SELL -94 16.650* 20.07 Profit of 1,887 on sale
2025-04-24 SELL -188 15.490* 20.24 Profit of 3,805 on sale
2025-04-17 SELL -94 12.740* 20.59 Profit of 1,936 on sale
2025-04-15 SELL -282 13.170* 20.76 Profit of 5,854 on sale
2025-04-14 SELL -282 13.270* 20.84 Profit of 5,878 on sale
2025-04-09 SELL -376 12.860* 21.12 Profit of 7,941 on sale
2025-04-07 SELL -658 11.600* 21.34 Profit of 14,044 on sale
2025-04-04 SELL -940 11.780* 21.46 Profit of 20,169 on sale
2025-03-31 BUY 94 13.595* 21.76
2025-03-19 SELL -188 14.820* 22.55 Profit of 4,239 on sale
2025-03-14 SELL -564 15.150* 22.87 Profit of 12,897 on sale
2025-03-13 SELL -188 14.890* 22.98 Profit of 4,320 on sale
2025-03-12 SELL -3,196 15.950* 23.08 Profit of 73,771 on sale
2025-03-07 SELL -188 16.690* 23.42 Profit of 4,404 on sale
2025-03-06 SELL -282 16.270* 23.53 Profit of 6,637 on sale
2025-03-03 SELL -94 15.200* 23.91 Profit of 2,247 on sale
2025-02-28 SELL -63,323 16.560* 24.03 Profit of 1,521,537 on sale
2025-02-26 SELL -261 18.890* 24.21 Profit of 6,318 on sale
2025-02-25 SELL -783 19.200* 24.29 Profit of 19,022 on sale
2025-02-18 BUY 1,305 21.790* 24.57
2025-02-13 BUY 261 21.310* 24.76
2025-02-12 BUY 261 20.820* 24.84
2025-02-11 BUY 783 20.580* 24.93
2025-02-06 BUY 2,340 22.530* 25.13
2025-01-27 BUY 260 23.190* 25.55
2024-12-30 BUY 1,300 20.240* 26.03
2024-12-06 BUY 1,040 24.890* 26.15
2024-12-05 BUY 260 23.320* 26.25
2024-12-04 BUY 1,300 23.700* 26.34
2024-11-29 BUY 1,300 25.000* 26.52
2024-11-27 BUY 1,040 25.160* 26.64
2024-11-26 BUY 260 24.680* 26.73
2024-11-21 BUY 1,300 24.220* 27.09
2024-11-20 BUY 780 24.420* 27.23
2024-11-18 BUY 3,110 24.180* 27.61
2024-11-12 BUY 2,072 29.890* 27.45
2024-11-08 BUY 1,295 31.350* 27.18
2024-11-07 BUY 3,885 29.600* 26.99
2024-11-06 BUY 518 29.550* 26.78
2024-10-31 BUY 259 25.960* 26.68
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-08-21	SELL	-94	15.230*	17.87 Profit of 1,680 on sale
2025-07-31	BUY	282	13.830*	17.92
2025-06-30	SELL	-188	13.990*	18.38 Profit of 3,456 on sale
2025-06-25	SELL	-94	14.450*	18.47 Profit of 1,736 on sale
2025-06-20	SELL	-188	13.890*	18.56 Profit of 3,490 on sale
2025-05-23	BUY	94	13.420*	19.30
2025-05-19	SELL	-94	13.910*	19.49 Profit of 1,832 on sale
2025-05-15	SELL	-282	14.160*	19.59 Profit of 5,524 on sale
2025-05-12	SELL	-94	14.800*	19.73 Profit of 1,855 on sale
2025-05-09	SELL	-94	14.370*	19.78 Profit of 1,859 on sale
2025-04-30	SELL	-94	16.650*	20.07 Profit of 1,887 on sale
2025-04-24	SELL	-188	15.490*	20.24 Profit of 3,805 on sale
2025-04-17	SELL	-94	12.740*	20.59 Profit of 1,936 on sale
2025-04-15	SELL	-282	13.170*	20.76 Profit of 5,854 on sale
2025-04-14	SELL	-282	13.270*	20.84 Profit of 5,878 on sale
2025-04-09	SELL	-376	12.860*	21.12 Profit of 7,941 on sale
2025-04-07	SELL	-658	11.600*	21.34 Profit of 14,044 on sale
2025-04-04	SELL	-940	11.780*	21.46 Profit of 20,169 on sale
2025-03-31	BUY	94	13.595*	21.76
2025-03-19	SELL	-188	14.820*	22.55 Profit of 4,239 on sale
2025-03-14	SELL	-564	15.150*	22.87 Profit of 12,897 on sale
2025-03-13	SELL	-188	14.890*	22.98 Profit of 4,320 on sale
2025-03-12	SELL	-3,196	15.950*	23.08 Profit of 73,771 on sale
2025-03-07	SELL	-188	16.690*	23.42 Profit of 4,404 on sale
2025-03-06	SELL	-282	16.270*	23.53 Profit of 6,637 on sale
2025-03-03	SELL	-94	15.200*	23.91 Profit of 2,247 on sale
2025-02-28	SELL	-63,323	16.560*	24.03 Profit of 1,521,537 on sale
2025-02-26	SELL	-261	18.890*	24.21 Profit of 6,318 on sale
2025-02-25	SELL	-783	19.200*	24.29 Profit of 19,022 on sale
2025-02-18	BUY	1,305	21.790*	24.57
2025-02-13	BUY	261	21.310*	24.76
2025-02-12	BUY	261	20.820*	24.84
2025-02-11	BUY	783	20.580*	24.93
2025-02-06	BUY	2,340	22.530*	25.13
2025-01-27	BUY	260	23.190*	25.55
2024-12-30	BUY	1,300	20.240*	26.03
2024-12-06	BUY	1,040	24.890*	26.15
2024-12-05	BUY	260	23.320*	26.25
2024-12-04	BUY	1,300	23.700*	26.34
2024-11-29	BUY	1,300	25.000*	26.52
2024-11-27	BUY	1,040	25.160*	26.64
2024-11-26	BUY	260	24.680*	26.73
2024-11-21	BUY	1,300	24.220*	27.09
2024-11-20	BUY	780	24.420*	27.23
2024-11-18	BUY	3,110	24.180*	27.61
2024-11-12	BUY	2,072	29.890*	27.45
2024-11-08	BUY	1,295	31.350*	27.18
2024-11-07	BUY	3,885	29.600*	26.99
2024-11-06	BUY	518	29.550*	26.78
2024-10-31	BUY	259	25.960*	26.68

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of DNLI

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	378,159	1,201	906,799	41.7%
2025-09-18	267,705	7,938	845,210	31.7%
2025-09-17	409,861	700	1,166,910	35.1%
2025-09-16	391,495	300	1,419,697	27.6%
2025-09-15	260,665	0	671,937	38.8%
2025-09-12	206,570	0	814,137	25.4%
2025-09-11	275,762	207	657,649	41.9%
2025-09-10	329,334	0	769,460	42.8%
2025-09-09	309,105	0	685,690	45.1%
2025-09-08	379,188	58	1,067,132	35.5%
2025-09-05	349,059	0	2,670,128	13.1%
2025-09-04	280,937	11,807	555,931	50.5%
2025-09-03	417,113	0	1,357,895	30.7%
2025-09-02	422,885	5,205	3,059,398	13.8%
2025-08-29	549,150	3	991,426	55.4%
2025-08-28	543,279	750	1,001,438	54.2%
2025-08-27	366,427	0	654,686	56.0%
2025-08-26	644,048	0	1,095,696	58.8%
2025-08-25	291,784	0	587,617	49.7%
2025-08-22	312,554	200	1,397,371	22.4%
2025-08-21	399,082	0	875,607	45.6%
2025-08-20	326,184	0	625,317	52.2%
2025-08-19	264,863	0	410,141	64.6%
2025-08-18	309,669	0	516,163	60.0%
2025-08-15	209,560	0	463,256	45.2%
2025-08-14	332,064	232	818,152	40.6%
2025-08-13	524,452	0	992,838	52.8%
2025-08-12	325,318	1,582	713,957	45.6%
2025-08-11	295,585	0	597,428	49.5%
2025-08-08	698,451	0	1,028,935	67.9%
2025-08-07	587,323	0	987,051	59.5%
2025-08-06	756,413	0	1,219,503	62.0%
2025-08-05	416,200	26,598	1,111,990	37.4%
2025-08-04	474,241	500	928,766	51.1%
2025-08-01	365,641	0	787,315	46.4%
2025-07-31	376,072	66	896,403	42.0%
2025-07-30	509,961	8	956,417	53.3%
2025-07-29	282,888	12	622,537	45.4%
2025-07-28	292,351	0	614,152	47.6%
2025-07-25	234,267	0	458,041	51.1%
2025-07-24	289,899	84	723,176	40.1%
2025-07-23	345,904	711	676,129	51.2%
2025-07-22	228,079	98	411,315	55.5%
2025-07-21	237,820	0	416,453	57.1%
2025-07-18	226,511	0	419,959	53.9%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE